Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting, 18911-18912 [2017-08177]
Download as PDF
jstallworth on DSK7TPTVN1PROD with NOTICES
Federal Register / Vol. 82, No. 77 / Monday, April 24, 2017 / Notices
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On May 17, 2017, the
VRBPAC will meet in an open session
to discuss considerations for evaluation
of Respiratory Syncytial Virus vaccine
candidates in seronegative infants. FDA
intends to make background material
available to the public no later than 2
business days before the meeting. If
FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 10, 2017. Oral
presentations from the public will be
scheduled between approximately 1:15
p.m. and 2:15 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before May 2,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 3, 2017.
VerDate Sep<11>2014
13:48 Apr 21, 2017
Jkt 241001
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact CAPT Serina
Hunter-Thomas at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at:
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08176 Filed 4–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Science Board to the Food and Drug
Administration Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Science Board to the
FDA. The general function of the
committee is to provide advice to the
Commissioner of Food and Drugs and
other appropriate officials on specific,
complex scientific and technical issues
important to FDA and its mission,
including emerging issues within the
scientific community. Additionally, the
Science Board provides advice to the
Agency on keeping pace with technical
and scientific developments including
in regulatory science, input into the
Agency’s research agenda and on
upgrading its scientific and research
facilities and training opportunities. It
will also provide, where requested,
expert review of Agency sponsored
intramural and extramural scientific
SUMMARY:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
18911
research programs. This meeting is open
to the public.
DATES: The meeting will be held on May
9, 2017, from 2 p.m. to 5 p.m.
ADDRESSES: FDA White Oak Campus,
10903 New Hampshire Ave, Bldg. 31,
Rm. 1404, Silver Spring, MD 20993.
This meeting will take place via audio
Webcast. To access the link for the
audio Webcast check the Agency’s Web
site at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link. Answers to
commonly asked questions including
information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
For those unable to access the audio
Webcast, a conference room with a
speakerphone will be reserved at the
meeting location provided at the top of
the ADDRESSES section. Seating is
limited and is available on a first come,
first served basis.
FOR FURTHER INFORMATION CONTACT:
Rakesh Raghuwanshi, Office of the
Chief Scientist, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave, Bldg. 1, Rm. 3309, Silver Spring
MD 20993, 301–796–4769,
rakesh.raghuwanshi@fda.hhs.gov, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington, DC area). A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The Science Board will
provide recommendations on the
Agency’s Innovation Funds work plan
as prescribed in section 1002 of the 21st
Century Cures Act (Pub. L. 114–255).
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
E:\FR\FM\24APN1.SGM
24APN1
jstallworth on DSK7TPTVN1PROD with NOTICES
18912
Federal Register / Vol. 82, No. 77 / Monday, April 24, 2017 / Notices
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 2, 2017. Oral
presentations from the public will be
scheduled between approximately 4
p.m. and 5 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before April 24,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 25, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Rakesh
Raghuwanshi at least 7 days in advance
of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08177 Filed 4–21–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
13:48 Apr 21, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Reducing the Risk of Preventable
Adverse Drug Events Associated With
Hypoglycemia in the Older Population;
Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration’s (FDA) Center for Drug
Evaluation and Research (CDER),
Professional Affairs and Stakeholder
Engagement Staff (PASES), is
announcing a 1-day public workshop
entitled ‘‘Reducing the Risk of
Preventable Adverse Drug Events
Associated with Hypoglycemia in the
Older Population.’’ The purpose of this
workshop is to discuss the importance
of individualized glycemic control
targets for older patients with diabetes;
to reduce the risk of serious
hypoglycemia; identify and discuss
medication safety efforts, both those that
are part of the Safe Use Initiative and
those external to FDA, that are of direct
relevance and importance to older
patients living with the disease; discuss
future areas of research which could be
explored to reduce the risk of serious
hypoglycemia in older diabetic patients;
and disseminate the results of this
discussion to inform patients, patient
advocates, and health care practitioners.
DATES: The public workshop will be
held on September 12, 2017, from 9 a.m.
to 4 p.m.
ADDRESSES: The public workshop will
be held at FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503), Silver Spring, MD 20993.
Entrance for the public workshop
participants (non-FDA employees) is
through Building 1, where routine
security check procedures will be
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Scott Winiecki, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 240–402–8824, email:
CDERSafeUseInitiative@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
I. Background
FDA CDER, PASES, is announcing a
1-day public workshop entitled
‘‘Reducing the Risk of Preventable
Adverse Drug Events associated with
Hypoglycemia in the Older Population.’’
The purpose of this workshop is to: (1)
Discuss the importance of
individualized glycemic control targets
for older patients with diabetes, in order
to reduce the risk of serious
hypoglycemia; (2) identify and discuss
medication safety efforts, both those that
are part of the Safe Use Initiative and
those external to FDA, that are of direct
relevance and importance to older
patients living with the disease; (3)
discuss future areas of research which
could be explored to reduce the risk of
serious hypoglycemia in older diabetic
patients; and (4) disseminate the results
of this discussion to inform patients,
patient advocates, and health care
practitioners.
II. Topics for Discussion at the Public
Workshop
The symposium will feature
presentations on the scope of
hypoglycemia-related adverse drug
events in the older population, the risks
and benefits of various degrees of
glycemic control, factors affecting
patient centered care, research into
effective diabetes management, and the
concept and translation of
individualized glycemic targets to
minimize adverse events in practice
settings. Presenters will represent
multidisciplinary backgrounds from
government, academia, patient safety
groups, health care industry, and
clinicians. There will be opportunities
for collaboration between speakers and
attendees as well as question and
answer sessions.
III. Participating in the Public
Workshop
Registration: To register for the public
workshop, please visit the following
Web site: https://wcms.fda.gov/FDAgov/
Drugs/NewsEvents/
ucm538666.htm?SSContributor=true.
Please provide complete contact
information for each attendee, including
name, title, affiliation, address, email,
and telephone.
Registration is free and based on
space availability, with priority given to
early registrants. Persons interested in
attending this public workshop must
register by August 29, 2017, midnight
Eastern Time. Early registration is
recommended because seating is
limited; therefore, FDA may limit the
number of participants from each
organization. If time and space permit,
E:\FR\FM\24APN1.SGM
24APN1
Agencies
[Federal Register Volume 82, Number 77 (Monday, April 24, 2017)]
[Notices]
[Pages 18911-18912]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08177]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Science Board to the Food and Drug Administration Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Science Board to the FDA. The
general function of the committee is to provide advice to the
Commissioner of Food and Drugs and other appropriate officials on
specific, complex scientific and technical issues important to FDA and
its mission, including emerging issues within the scientific community.
Additionally, the Science Board provides advice to the Agency on
keeping pace with technical and scientific developments including in
regulatory science, input into the Agency's research agenda and on
upgrading its scientific and research facilities and training
opportunities. It will also provide, where requested, expert review of
Agency sponsored intramural and extramural scientific research
programs. This meeting is open to the public.
DATES: The meeting will be held on May 9, 2017, from 2 p.m. to 5 p.m.
ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave, Bldg. 31, Rm.
1404, Silver Spring, MD 20993. This meeting will take place via audio
Webcast. To access the link for the audio Webcast check the Agency's
Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory committee meeting link. Answers
to commonly asked questions including information regarding special
accommodations due to a disability, visitor parking, and transportation
may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
For those unable to access the audio Webcast, a conference room
with a speakerphone will be reserved at the meeting location provided
at the top of the ADDRESSES section. Seating is limited and is
available on a first come, first served basis.
FOR FURTHER INFORMATION CONTACT: Rakesh Raghuwanshi, Office of the
Chief Scientist, Office of the Commissioner, Food and Drug
Administration, 10903 New Hampshire Ave, Bldg. 1, Rm. 3309, Silver
Spring MD 20993, 301-796-4769, rakesh.raghuwanshi@fda.hhs.gov, or FDA
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in
the Washington, DC area). A notice in the Federal Register about last
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to
the appropriate advisory committee meeting link, or call the advisory
committee information line to learn about possible modifications before
coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The Science Board will provide recommendations on the
Agency's Innovation Funds work plan as prescribed in section 1002 of
the 21st Century Cures Act (Pub. L. 114-255).
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee
[[Page 18912]]
meeting, and the background material will be posted on FDA's Web site
after the meeting. Background material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the
appropriate advisory committee meeting link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before May
2, 2017. Oral presentations from the public will be scheduled between
approximately 4 p.m. and 5 p.m. Those individuals interested in making
formal oral presentations should notify the contact person and submit a
brief statement of the general nature of the evidence or arguments they
wish to present, the names and addresses of proposed participants, and
an indication of the approximate time requested to make their
presentation on or before April 24, 2017. Time allotted for each
presentation may be limited. If the number of registrants requesting to
speak is greater than can be reasonably accommodated during the
scheduled open public hearing session, FDA may conduct a lottery to
determine the speakers for the scheduled open public hearing session.
The contact person will notify interested persons regarding their
request to speak by April 25, 2017.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Rakesh Raghuwanshi at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-08177 Filed 4-21-17; 8:45 am]
BILLING CODE 4164-01-P